Influence of Dyslipidemia on the Quality of Sexual Life in Women in the Menacme using a Combined Oral Contraceptive

Strufaldi, Rodolfo; Pompei, Luciano Melo; Steiner, Marcelo Luis; Fernandes, César Eduardo

doi:10.1055/s-0036-1597695

Acessibilidade / Reportar erro

Brasil

Revista Brasileira de Ginecologia e Obstetrícia

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

ORIGINAL ARTICLE • Rev. Bras. Ginecol. Obstet. 38 (12) • Dec 2016 • https://doi.org/10.1055/s-0036-1597695 copy

Influence of Dyslipidemia on the Quality of Sexual Life in Women in the Menacme using a Combined Oral Contraceptive

Influência da dislipidemia na qualidade de vida sexual de mulheres na menacme usando contraceptivos orais combinados

Authorship SCIMAGO INSTITUTIONS RANKINGS

ABSTRACT

Purpose:

Female sexual dysfunction is a complex and common condition that affects women, and the relationship between sexual function and dyslipidemia is poorly studied. This study aims to assess this relationship in the reproductive life women in the menacme who use combined oral contraceptives (COCs) .

Methods:

A total of 49 healthy women who were sexually active received COC pills that contained ethinylestradiol 30 mcg (EE30) plus levonorgestrel 150 mcg (LNG150). The women were divided into two groups according to their lipid profiles. Dyslipidemia was defined as a high-density lipoprotein (HDL) level < 50 mg/dL or a low-density lipoprotein (LDL) level > 130 mg/dL. Sexual function was assessed using the Female Sexual Function Index (FSFI) Questionnaire. Lipid and lipoprotein parameters were obtained at baseline and after the sixth cycle.

Results:

After six cycles of the COCs, the total cholesterol and LDL cholesterol levels in the women with a LDL level > 130 mg/dL decreased by 14.7% and 22.1% respectively. In the women with a HDL level < 50 mg/dL at baseline, the HDL level increased by 15.5% at the end of the study. The arousal and orgasm domains and the FSFI total scores significantly increased in women with and without dyslipidemia. The desire and satisfaction domains increased only in the group without dyslipidemia at the end of the treatment period.

Conclusions:

The EE30/LNG150 formulation increased the sexual function and it was only positively correlated with the HDL cholesterol level. These data indicated a low correlation between sexual function and the changes in the lipid and lipoprotein metabolism.

Keywords:
combined oral contraceptive; quality of sexual life; female sexuality; sexual function questionnaire; dyslipidemia

Characteristics	LDL Group (n = 49)			HDL Group (n = 49)
Characteristics	LDL < 130 mg/dL(n = 34)	LDL ≥ 130 mg/dL(n = 15)	p	HDL ≥ 50 mg/dL(n = 31)	HDL < 50 mg/dL(n = 18)	p
Age (years)	27.6 ± 6.4	31.2 ± 7.4	0.087	28.2 ± 7.1	29.7 ± 6.4	0.456
Ethnicity (Caucasian)	17 (69.3%)	12 (30.7%)	0.049	21 (63.2%)	8 (36.8%)	0.110
Smoking (%)	8 (23.5%)	3(20.0%)	0.549	5 (16.1%)	6 (33.3%)	0.150
Duration of relationship (years)	5.9 ± 4.8	8.9 ± 7.1	0.138	7.4 ± 6.3	5.9 ± 4.5	0.723
Weight (kg)	60.7 ± 10.4	60.3 ± 9.0	0.893	60.1 ± 8.9	61.4 ± 11.7	0.654
BMI (kg/m²)	23.8 ± 3.2	24.3 ± 2.6	0.616	23.8 ± 2.8	24.3 ± 3.3	0.569
Abdominal circumference (cm)	79.5 ± 9.8	81.1 ± 8.1	0.598	78.5 ± 8.5	82.5 ± 10.3	0.153
Fasting glucose (mg/dL)	82.8 ± 9.3	79.3 ± 8.5	0.221	81.8 ± 9.8	81.5 ± 8.2	0.911
Total cholesterol (mg/dL)	175.2 ± 21.2	223.9 ± 18.7	< 0.001	190.5 ± 29.3	189.3 ± 33.1	0.894
LDL cholesterol (mg/dL)	99.7 ± 19.6	145.3 ± 15.1	< 0.001	113.8 ± 29.5	113.3 ± 25.8	0.952
HDL cholesterol (mg/dL)	53.4 ± 11.0	52.1 ± 7.7	0.700	58.7 ± 7.3	43.1 ± 5.2	< 0.001
Triglycerides (mg/dL)	103.3 ± 53.6	127.1 ± 77.0	0.224	91.9 ± 32.8	142.7 ± 84.8	0.087

Characteristics	LDL Group (n = 49)			HDL Group (n = 49)
Characteristics	LDL < 130 mg/dL(n = 34)	LDL ≥ 130 mg/dL(n = 15)	p (intergroup comparison)	HDL ≥ 50 mg/dL(n = 31)	HDL < 50 mg/dL(n = 18)	p (intergroup comparison)
Weight (kg)
Baseline	60.7 ± 10.4	60.3 ± 9.0	0.893	60.1 ± 8.9	61.4 ± 11.7	0.654
After six cycles	60.6 ± 10.3	60.5 ± 9.5	0.979	60.4 ± 8.8	61.0 ± 12.0	0.838
Intragroup comparison	p = 0.713	p = 0.586		p = 0.317	p = 0.205
BMI (kg/m²)
Baseline	23.8 ± 3.2	24.3 ± 2.6	0.616	23.8 ± 2.8	24.3 ± 3.3	0.569
After six cycles	23.8 ± 3.1	24.4 ± 2.7	0.531	23.9 ± 2.8	24.2 ± 3.5	0.808
Intragroup comparison	p = 0.872	p = 0.574		p = 0.242	p = 0.243
Abdominal circumference (cm)
Baseline	79.5 ± 9.8	81.1 ± 8.1	0.598	78.5 ± 8.5	82.5 ± 10.3	0.153
After six cycles	79.4 ± 11.3	79.1 ± 7.3	0.923	77.6 ± 8.4	82.1 ± 12.4	0.136
Intragroup comparison	p = 0.804	p = 0.060		p = 0.116	p = 0.761
Fasting glucose (mg/dL)
Baseline	82.8 ± 9.3	79.3 ± 8.5	0.221	81.8 ± 9.8	81.5 ± 8.2	0.911
After six cycles	82.0 ± 4.6	82.7 ± 4.6	0.610	83.3 ± 4.7	80.3 ± 3.8	0.026
Intragroup comparison	p = 0.622	p = 0. 170		p = 0.350	p = 0. 616
Total cholesterol (mg/dL)
Baseline	175.2 ± 21.2	223.9 ± 18.7	< 0.001	190.5 ± 29.3	189.3 ± 33.1	0.894
After six cycles	176.4 ± 22.5	191.2 ± 19.6	0.032	183.2 ± 20.1	176.9 ± 26.5	0.348
Intragroup comparison	p = 0.759	p < 0.001		p = 0.131	p = 0.050
HDL cholesterol (mg/dL)
Baseline	53.4 ± 11.0	52.1 ± 7.7	0.700	58.7 ± 7.3	43.1 ± 5.2	< 0.001
After six cycles	54.1 ± 7.4	56.2 ± 11.0	0.429	57.6 ± 8.3	49.7 ± 6.9	0.001
Intragroup comparison	p = 0.623	p = 0.115		p = 0.469	p = 0.001
LDL cholesterol (mg/dL)
Baseline	99.7 ± 19.6	145.3 ± 15.1	< 0.001	113.8 ± 29.5	113.3 ± 25.8	0.952
After six cycles	101.6 ± 21.0	113.2 ± 23.3	0.092	105.3 ± 22.3	104.9 ± 22.5	0.948
Intragroup comparison	p = 0.542	p < 0.001		p = 0.075	p = 0.115
Triglycerides (mg/dL)
Baseline	103.3 ± 53.6	127.1 ± 77.0	0.224	91.9 ± 32.8	142.7 ± 84.8	0.087
After six cycles	105.6 ± 39.3	115.9 ± 34.5	0.384	103.9 ± 35.3	117.1 ± 41.6	0.244
Intragroup comparison	p = 0.630	p = 0.564		p = 0.008	p = 0.109

Domain (range of score)	LDL Group (n = 49)			HDL Group (n = 49)
Domain (range of score)	LDL < 130 mg/dL(n = 34)	LDL ≥ 130 mg/dL(n = 15)	p (intergroup comparison)	HDL ≥ 50 mg/dL(n = 31)	HDL < 50 mg/dL(n = 18)	p (intergroup comparison)
FSFI-Desire (1.2–6.0)
Baseline	3.9 ± 0.7	3.8 ± 0.5	0.781	3.8 ± 0.6	3.9 ± 0.7	0.712
After six cycles	4.1 ± 0.7	3.8 ± 0.6	0.185	4.0 ± 0.7	4.1 ± 0.7	0.966
Intragroup comparison	p = 0.013	p = 0.673		p = 0.058	p = 0.093
FSFI-Arousal (0.0–6.0)
Baseline	3.9 ± 1.0	3.9 ± 0.9	0.991	3.9 ± 1.0	3.8 ± 1.1	0.551
After six cycles	4.0 ± 0.9	4.1 ± 0.8	0.913	4.1 ± 0.8	3.9 ± 0.9	0.378
Intragroup comparison	p = 0.008	p = 0.043		p = 0.005	p = 0.068
FSFI-Lubrication (0.0–6.0)
Baseline	4.9 ± 1.2	5.5 ± 0.8	0.034	5.1 ± 1.2	5.0 ± 1.1	0.559
After six cycles	5.0 ± 1.1	5.5 ± 0.8	0.081	5.1 ± 1.0	5.1 ± 1.0	0.806
Intragroup comparison	p = 0.052	p = 0.655		p = 0.345	p = 0.273
FSFI-Orgasm (0.0–6.0)
Baseline	4.7 ± 1.3	4.8 ± 1.2	0.800	4.8 ± 1.3	4.6 ± 1.2	0.454
After six cycles	5.0 ± 1.0	5.0 ± 0.8	0.648	5.1 ± 1.0	5.0 ± 1.0	0.609
Intragroup comparison	p = 0.004	p = 0.04		p = 0.010	p = 0.012
FSFI-Satisfaction (0.8–6.0)
Baseline	4.5 ± 1.1	4.7 ± 1.1	0.541	4.7 ± 1.0	4.3 ± 1.3	0.407
After six cycles	4.9 ± 0.9	4.9 ± 0.9	0.825	5.0 ± 0.8	4.7 ± 1.0	0.393
Intragroup comparison	p < 0.001	p = 0.093		p < 0.001	p = 0.004
FSFI-Pain (0.0–6.0)
Baseline	5.2 ± 1.2	5.7 ± 0.6	0.224	5.4 ± 1.0	5.2 ± 1.2	0.448
After six cycles	5.3 ± 1.1	5.7 ± 0.6	0.301	5.5 ± 0.9	5.3 ± 1.2	0.772
Intragroup comparison	p = 0.068	p = 1.000		p = 0.285	p = 0.109
FSFI-Total Score (2.0–36.0)
Baseline	27.0 ± 5.3	28.3 ± 3.0	0.688	27.7 ± 4.6	26.9 ± 5.1	0.507
After six cycles	28.5 ± 4.5	29.0 ± 2.8	0.888	28.9 ± 3.9	28.3 ± 4.4	0.648
Intragroup comparison	p < 0.001	p = 0.004		p < 0.001	p < 0.001

Federação Brasileira das Sociedades de Ginecologia e Obstetrícia Av. Brigadeiro Luís Antônio, 3421, sala 903 - Jardim Paulista, 01401-001 São Paulo SP - Brasil, Tel. (55 11) 5573-4919 - Rio de Janeiro - RJ - Brazil
E-mail: editorial.office@febrasgo.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] Address for correspondence: Rodolfo Strufaldi, MD, PhD, Faculdade de Medicina do ABC, Departamento de Ginecologia, Av. Príncipe de Gales 821, 2°andar. Santo André, SP, Brasil, CEP- 09060-650 (e-mail: rostrufaldi@gmail.com)